The TuBerculosis Vaccine Initiative (TBVI) is a Research and Innovation partnership that works to discover and develop new, safe and effective TB vaccines that are accessible and affordable for all people.
A non-profit foundation, TBVI creates an enabling environment for TB vaccine research and innovation (R&I) and product development. TBVI supports R&D partners to develop and move the most promising TB vaccine and biomarker candidates through the pipeline. To continue to innovate and diversify the pipeline and TB vaccine platforms, TBVI supports collaborative research and innovation by its R&D partners. TBVI adds value through providing services of technical advice for product development; project identification, development and management; and resource mobilisation. TBVI works through the Global TB Vaccine Partnership (GTBVP) with global stakeholders to strengthen Global and European cooperation and coordination and identify and address gaps to move the field forward.
To make decisions to select/down select vaccine candidates in an objective and transparent manner and to use the available financial resources effectively, TBVI assesses and manages its portfolio based on criteria in its TB Vaccine Development Pathway tool. It seeks to align its R&I activities with other global efforts, in particular with Global partners in the Global TB Vaccine Partnership (GTBVP).
TBVI does not have its own commercial interests. Ownership of vaccine candidates and biomarkers, and any intellectual property rights remain with researchers and vaccine developers. This enables TBVI to be a neutral and honest broker among its R&D partners, global stakeholders and funders.
Access and affordability of TB vaccines is a statutory objective of TBVI and is a commitment that is part of each project grant agreement supported by TBVI.
TBVI and its R&D partners have developed over 50% of the current candidates in the TB vaccine pipeline
TBVI’s work in the next two years will focus on:
- product development – moving current leading TB vaccine and biomarker candidates and fast followers through the pipeline
- collaborative research and innovation – continuing to innovate and diversify the TB vaccine and biomarker pipeline and TB vaccine platforms; develop and test alternative vaccine routes and delivery mechanisms; develop and validate pre-clinical models; develop human challenge models; develop next generation portfolio management tools; and harness the power of AI for TB vaccine and biomarker research and clinical trials.
- Global and European Cooperation and Coordination of TB vaccine R&I efforts, including identifying and addressing key gaps to move the TB vaccine R&I field forward.